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Abstract 
Mirtazapine is an often used antidepressant drug; however insufficient 
information is available regarding its safety during pregnancy. Therefore, this 
work was initiated to study the effect of prenatal exposure of mirtazapine on 
postnatal developments of rats. The study was conducted on pregnant rats to 
observe the safety profile of mirtazapine in comparison to control. The 
percentage weight gain, gestation period and litter size of the rats treated with 
double therapeutic dose (DTD) was significantly lower than the rats treated with 
therapeutic dose (TD) and rats of control group. However the litter size of the 
TD treated rats was also found smaller than the control. The offspring were 
examined through battery of test in order to evaluate their developmental 
neurotoxicity. The test includes the assessment of postnatal growth, reflex 
ontogeny, neuromotor abilities, activity level, emotional reactivity and learning 
ability. The DTD exposure negatively affected on overall growth of pups in 
comparison to TD exposed pups and control group. Further, the amine 
concentration in brain was also found significantly lower in DTD exposed pups. 
Therefore, this study reveals that the treatment of pregnant rats with TD and 
DTD decreases their litter size. In addition the prenatal exposure of DTD of 
mirtazapine negatively affects on neurodevelopment of rats.  
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Introduction 
Recent studies [1–3] suggest that the adverse fetal effects are associated with 
antidepressant drug exposure during pregnancy. However, further studies are necessary 
to measure the consequences of newer antidepressants fetal exposure such as 
mirtazapine. Mirtazapine is an atypical antidepressant agent, it is used not only for 
treatment of depression and anxiety but also for treatment of nausea and hyper emesis 
gravid arum [4, 5].  
There is little information available on the safety of mirtazapine usage during pregnancy. In 
some studies [6–9] on mirtazapine exposure in pregnancy reported that out of 104 
pregnancy outcomes; 77 live births, 1 stillbirth, 20 spontaneous abortions, 6 therapeutic 
abortions, and 2 major malformations were observed. In another fertility study [10] on rats, 
100 mg/kg doses of mirtazapine were not affected on mating and conceptions, but it leads 
to pre-implantation losses. Further, the estrous cycle was found disrupted with 3 times or 
higher doses of maximum recommended human dose (~5 mg/kg). These studies provided 
necessary indication and raised significant concern about the safe usage of mirtazapine 
during pregnancy. Therefore, the current investigation was undertaken to quantify the risk 
associated with the mirtazapine usage in pregnancy. Primarily, the physical and behavioral 
development were explore related to the prenatal exposure of mirtazapine. 
Results and Discussion 
The in utero exposure of mirtazapine on postnatal development of offspring was explored 
and the two different doses i.e. double therapeutic dose (DTD) and (TD) were 
administered during 6
th to 20
th day of pregnancy. The pregnant rats were monitored for 
changes during gestation period and litter size. Further, the offspring were examined for 
neurobehavioral developments.  
The physical development of offspring was assessed by observing for eye opening, pinna 
detachment and eruption of incisors. The behavioral ontogeny of pups was inspected with 
surface righting reflex test, negative geotaxis test and ascending wire mesh test. The 
motor development of pups was evaluated using swimming development test and rota rod 
test. The spatial memory of the pups was tested with Morris water maze test. Finally the 
pups were sacrificed and the brain amines were estimated. 
Maternal observations 
The pregnant rats were treated with TD or DTD during 6
th to 20
th day of pregnancy. The 
rats which were treated with DTD have shown significantly lower percentage weight gain 
on day 9 (F 2, 46 = 7.65, p<0.01); on day 12 (F 2, 46 = 8.58, p<0.01); on day 15 (F 2, 46 = 
9.22, p<0.01) and on day 18 (F 2, 46 = 8.77, p<0.01) than TD treated rats and control 
groups rats (Fig.1.B). The gestational period of the DTD treated rats was significantly 
shorter (F2, 21 = 3.32, p<0.05) than TD treated and control group (Fig.1.A). One of the most 
remarkable observation was that, litter size of mirtazapine [DTD (F2, 21 = 18.73, p<0.001) or 
TD (F 1, 14 = 13.42, p<0.01)] treated rats was significantly smaller than that of control 
(Fig.1.A). 
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A. Gestational period and litter size of dams B. Percentage weight gain of dams 
Fig. 1.   Effect of mirtazapine on pregnant rats.  
A: DTD treated dams showed significantly lower gestational period (p<0.05) and 
litter size (p<0.001) as compared to TD treated dams and control group dams. 
Litter size of TD treated dams was also significantly lesser (p<0.01) than 
control.  
B: Percentage weight gain of DTD treated dams was significantly lower 
(p<0.01) on gestational day 9, 12, 15 and 18 as compared to TD treated dams 
and control group dams. Data analysis: one way ANNOVA followed by post hoc 
tukey. 
A. Physical development of pups  B. Weight gain of pups 
Fig. 2.   Effect of mirtazapine on physical developments.  
A: DTD exposed pups pinna detachment, eruption of incisors and pinna 
detachment was significantly (p<0.05) slower than TD exposed pups and 
control.  
B: DTD exposed litters gained significantly (p<0.05) lower weight on PND 0 and 
PND 3 than TD exposed litters and control group litters. Data analysis: one way 
ANNOVA followed by post hoc tukey. 
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The above results suggest that the mirtazapine possess feto-toxic effects. These 
observations are in congruence with earlier studies [6–9], which reports the spontaneous 
abortions and major malformation associated with mirtazapine exposure.  
Physical development 
The physical development of the DTD exposed pups were different from TD exposed and 
control group pups. DTD induced significant reductions in body weight on day 0 (F2,46 = 
1.68, p<0.05) and day 3 (F2,46=1.33, p<0.05) than TD exposed and control pups (Fig 2, B).  
The DTD exposed pups pinna detachment (F2,46 = 1.56, p<0.05), eruption of incisors (F2,46 
= 2.11, p<0.05) and eyes opening (F2,46 = 2.48, p<0.05) was delayed in comparison to TD 
exposed pups and control (Fig 2, A).  
Behavioral development 
The effect of in utero exposure of mirtazapine (TD or DTD) on behavioral development of 
pups was explored at various stages of life. The pups were tested for surface righting 
reflex activity from 4
th to 8
th PND. The drug exposed pups were found less active than the 
control pups: DTD exposed (F 2, 46 = 8.55, p<0.01), TD exposed (F 2, 32 = 5.62, p<0.01). 
The negative geotaxis movement of pups was tested from 8
th to 12
th PND. The DTD 
exposed pups took more time to turn to 180˚, on PND 8 (F2, 46 = 9.21; P<0.01), PND 10 (F2, 
46 =8.67; P<0.01) and PND 12 (F2, 46 = 8.43; P<0.01)]) than TD exposed and control pups. 
The pups were examined for ascending wire mesh activity on PND 14
th to 18
th. The DTD 
exposed pups took more time than the TD exposed and control group pups specifically on 
PND 14 (F2, 46 = 7.46; P<0.01) and PND 18 (F2, 46 = 8.33; P<0.01)].  
The swimming ability of pups was tested from 6
th to 12
th PND. The drug exposed pups 
were inefficient than the control pups: DTD (F2, 46 = 9.21; P<0.01) and TD (F2, 32 = 3.52; 
P<0.05). The pups’ motor ability was investigated on 22
nd and 59
th PND using rota rod. 
The DTD exposed pups spent shorter time on rod than the TD exposed and control pups: 
on PND 22 (F2, 46 = 2.13; P<0.05) and on PND 59 (F2, 46 = 1.69; P<0.05).  
Thus, the above result reveals the prenatal exposure of mirtazapine affected the motor 
development of pups. The present study supports the earlier report [14, 15], which suggest 
that the children exposed with serotonin reuptake inhibitors, displayed subtle changes in 
motor development and in motor movement control. In addition, the various studies 
[16, 17] suggest that the prenatal exposure of most of the antidepressants affects on motor 
development of offspring.  
Emotional reactivity  
The exploratory activity of the pups was investigated on 18
th, 35
th and 56
th PND. The pups 
which were in utero exposed to mirtazapine (both TD and DTD) were more active on PND 
18 i.e. increase in total crossing (F2, 46 = 1.21; P<0.05). The pups which were in utero 
exposed to DTD were less active on PND 35 and 56 i.e. decrease in total crossing (F2, 46 = 
1.78.; P<0.05) than control (Fig 4. A). The above discussed results were not conclusive. 
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A. Surface righting reflex  B. Negative geotaxis test 
   
C. Wire mesh ascending test  D. Swimming development 
 
E. Rota rod test 
Fig. 3.  Effect of mirtazapine on motor development.  
A: DTD and TD exposed pup’s surface righting reflex was significantly (p<0.01) 
delayed than control.  
B: Swimming development of DTD exposed pups was significantly (p<0.01) 
poor than TD exposed pups and control.  
C: Negative geotaxis tests showed DTD exposed pups took significantly 
(p<0.01) more time than TD exposed pups and control.  
D: Ascending wire mesh test revealed DTD exposed pups took significantly 
(p<0.01) more time than TD exposed pups and control.  
E: Rota rod test showed DTD exposed pups spend significantly (p<0.05) less 
time on rod than TD exposed pups and control. Data analysis: one way 
ANNOVA followed by post hoc tukey. 
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The anxiety associated behavior of pups was explored on PND 30 using plus maze. The 
pups which were exposed to mirtazapine specifically DTD, were more anxious than TD 
exposed pups and control group pups. They executed lower number of entries (F2, 46 = 
10.49; P<0.01); and spent lesser time (F2, 46 = 11.72; P<0.01) on open arm (Fig 4. B).  
From the above study the DTD exposed pups were observed as more anxious than the TD 
exposed and control pups. The discussed anxious behavior may be due to the effect of 
mirtazapine on serotonin neurotransmission. The earlier reports [18–21] also reveal the 
increased anxiety and depression like behavior through serotonin transporter knockout 
mice. The additional studies [22–24] related to prenatal exposure of selective serotonin 
reuptake inhibitors followed to irritability and aggression in offspring. 
Cognitive response 
The detrimental effects are potentially associated with exposure of substances throughout 
or later in pregnancy on neurobehavioral and cognitive development [25]. Therefore, effect 
of mirtazapine exposure on cognition and memory of the pups was studied on PND 24 and 
61. The DTD exposed pups showed poor learning ability on PND 24 [they took more time 
(F2, 46 = 1.78; P<0.05) to escape to the platform in Morris water maze test] than the TD 
exposed and control group pups (Fig 4. C). Whereas on PND 61 the drug exposed pups 
were not different from control pups in their learning ability.  
The present investigation did not provide any significant difference between cognition of 
TD exposed pups and control. However, the significant difference was observed between 
the DTD exposed pups and control pup on PND 24. The observe difference was may be 
due to any developmental neurotoxicity with higher doses. Further investigation may 
warrant consolidating the claim. The overall results are comparable with previous studies 
[26], where antidepressants produced in-significant effect of on cognition. Though, the 
identified studies varied considerably in their own methodology, including the age of the 
children studied, the scales and assessments used.  
Biochemical aspects 
The amniotic fluid of drug treated rats was analyzed. The TD treated rat’s placental drug 
concentration was 8 ± 0.19 µg/ml (n=8) and the DTD rat’s placental concentration was 13 
± 0.15 µg/ml (n=8). Therefore, the concentration of drug in placenta increased with 
increase in drug dose. The concentration of amines of pup’s brain was estimated on PND 
62. The Noradrenaline and Dopamine concentration was found significantly (F2, 46 = 4.69; 
P<0.05) lower in brains of DTD exposed pups in comparison to TD exposed and control 
(Fig. 4. D).  
Therefore, the lower concentration of amines in the brain of DTD exposed pups may be 
responsible for their behavioral changes. The previous reports also suggest the tropic role 
of monoamines on brain morphogenesis [27–29].  
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A. Crossing, grooming and rearing of pups (open field test) 
   
B. Elevated plus maze test  C. Modified water maze test 
 
D. Brain amines 
Fig. 4.   Effect of mirtazapine on behavior.  
A: Open field test: TD and DTD exposed pups were significantly (p<0.05) more 
active on PND 18 but less active on PND 56 compared to control. 
B: Plus maze test: DTD exposed pups spent significantly (p<0.01) less time and 
number of entries than TD exposed pups and control.  
C: Modified water maze: DTD exposed pups on PND 24 took significantly 
(p<0.05) more time than TD exposed pups and control. 
D: DTD exposed pup’s Noradrenaline & Dopamine was significantly (p<0.05) 
lesser, serotonin was similar to TD exposed pups and control. Data analysis: 
one way ANNOVA followed by post hoc tukey. 
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Experimental 
Animals  
Thirty-six inbred Wistar albino rats, twenty-seven female and nine male (90–120 days old, 
weighing 120–150 gm) were selected. One male and three females were kept together for 
mating. Twenty four rats were confirmed pregnant by observing sperm in their vaginal 
smear and gestational day zero was assigned. All animals were maintained in the 
standard laboratory condition (25±2°C, humidity 55–60%) with alternate light and dark 
cycle (12/12  h). They were allowed standard pellet diet and water ad libitium. All 
experiments were performed as per Institutional Animals Ethics committee (IAEC), 
granting certification BIT/PH/IAEC/07/2007. 
Drug Administration 
Mirtazapine was procured from Sun Pharmaceutical Industries, Jammu, India. Two doses 
were selected for study 3.6 mg/kg, therapeutic dose (TD) and 7.2 mg/kg, double the 
therapeutic dose (DTD) (http://www.genepharm.com.au). Twenty-four pregnant rats were 
divided as follows: control group (no treatment), TD group and DTD group. Drug was 
administered orally dissolved in distilled water, at 10 am daily (6th to 20th day of gestation 
period). Dose was decided regularly according to the weights of dams.  
Examination of dams and pups 
Pregnant rat’s (dams) gestation period and percentage weight gain was recorded on every 
3rd day. After delivery their litter size and litter weights were recorded. After birth, pups 
were allowed for 21 days weaning. During weaning period pups of each litter were 
weighed regularly on every 3rd day. Pups day of eye opening, pinna detachment and 
eruption of incisors were observed. 
Motor development and behavioral development studies  
Behavior of pups was studied as follows: two pups of each mother rat, i.e. sixteen pups 
from each group were selected and they were subjected to the following behavioral tests: 
surface righting reflex, swimming development, negative geotaxis, ascending wire mesh, 
rotarod test, elevated plus maze, open field exploration, modified water maze (refer 
supporting information).  
Experimental protocol for motor development and behavioral development studies  
Surface righting reflex 
Each pup was placed in a supine position and allowed a maximum time of 2s to upright 
itself, two trials were given per day from 4th to 8th PND (post natal day). Day of 
achievement of righting reflex was recorded. 
Swimming development 
Pups were placed in water filled Plexi-glass container (40 x 30 x 14 cms) for 15 s on their 
PND 6, 8, 10 and 12. They were scored for angle of body (position of head in relation to 
surface of water) and limb movement. 
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Negative geotaxis 
Pups were placed on an inclined (30°) surface with their heads facing downward. The time 
necessary to turn to 90° and subsequently to 180° was recorded. They were tested for 90s 
on PND 8 to PND 12.  
Ascending wire mesh 
The wire mesh (50 x 30 cms) was dipped in water bath at 26°C such that it is 31 cm above 
the water surface. The pups on PND 14 to PND 18 pups were placed with their quarter 
hind and tail dipping in the water. Day of achievement of the pups to the top within 30 s 
was recorded.  
Rotarod test 
The pups were given a preliminary test for 20 s then they were placed on the rod and 
turned at 25 rpm. Time taken by rat to stay on the rod without falling was recorded. Four 
such trials were done on PND 22 and 59.  
Elevated plus maze 
This task measures the response to fear of falling; it was performed by pups on PND 30. 
The maze consisted of 2 walled arms and 2 open arms that were elevated 38 cm above 
the floor. Number of entries and time spent on the open arm was recorded within 5 min of 
observation.  
Open field exploration 
A semi-soundproof room with a constant temperature was used. The home cage of 
animals was transferred into the room 1 h before testing. The floor was divided into 16 
squares with plastic board (45 cm×45 cm). The rat was placed in the central area and 
latency to leave this area was recorded. Motor activity was expressed as a total number of 
squares crossed (with all four feet on one square) during the period of testing, horizontal 
activity (grooming) and vertical activity (total number of rearing). This study was performed 
on PND 18, 35 and 56  
Modified water maze 
The maze measured 100 cm in width and 80 cm in length was partitioned with wooden 
slants (12 cm width). On PND 24 and 61, the rats were placed in the one corner of the 
water maze (26°C). The time taken to escape from the maze to the platform was recorded. 
Each rat was given 6 consecutive trials with 1 min interval.  
Biochemical analysis 
Brain of each rat was rapidly removed by decapitation on PND 62 and stored at -20
°C till 
homogenization. The concentrations of Dopamine (DA), Noradrenaline (NA) and Serotonin 
(5-HT) were determined by the method of Ansell and Besin [11].  
Mirtazapine was assayed as described by Santana and Bonato [12]. Absorption maximum 
was found at 315.4nm. The concentration of mirtazapine in the amniotic fluid of rats was 
determined using the method of Buznikov [13]. Two groups of pregnant rats were selected. 
One group was treated (6
th to 15
th day of gestation) with TD and other with DTD. On 15th 
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day, 2hr after last dose, rats of both groups were sacrificed, uteri were dissected and the 
amniotic fluids were collected. The collected amniotic fluid was used for determining the 
concentration of mirtazapine.  
Statistical Analysis 
Two pups per litter (one male and one female) altogether sixteen pups per group were 
randomly selected. Number of pups per litter in each group was maintained to avoid 
inflation due to sample size. Results were analyzed using one way repeated measures 
ANOVA. When day specific models reached the criterion of significance Post hoc tukey 
test was done. The significance level was set at p<0.001 to 0.05 as per requirement. The 
data were presented as Mean ± SEM. 
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